Table 3.
Subject demographics of the 11 selected RCTs.
| Trial | Gemigliptin dose | Subject number | Age (years) | Men (%) | BMI (kg/m2) | Baseline HbA1c (%) | Baseline FPG (mg/dl) |
|---|---|---|---|---|---|---|---|
| Comparator dose | |||||||
| Rhee 2010 | GEM 50 mg | 35 | 52.4 | 71.4 | 25.14 | 8.24 | 162.9 |
| PBO | 34 | 51.3 | 67.6 | 25.56 | 8.2 | 151.2 | |
| Yang 2013 | GEM 50 mg | 87 | 54 | 65.5 | 25.4 | 8.2 | 155.8 |
| PBO | 87 | 52 | 50.6 | 26.7 | 8.3 | 159.7 | |
| Yoon 2017 | GEM 50 mg | 64 | 61.7 | 59.4 | 26 | 8.3 | 156.6 |
| PBO | 66 | 62.3 | 57.6 | 26.5 | 8.4 | 150.6 | |
| Lim 2017 | GEM 50 mg + MET | 136 | 54.4 | 57.4 | 25.8 | 8.65 | 172.7 |
| PBO + MET | 148 | 54 | 60.1 | 25.8 | 8.73 | 178.6 | |
| PBO + GEM 50 mg | 140 | 53.4 | 57.1 | 26.1 | 8.66 | 169.7 | |
| Ahn 2017 | GEM 50 mg + MET + GLM | 107 | 61.4 | 37.4 | 25.1 | 8.2 | 145.8 |
| PBO + MET + GLM | 109 | 60.4 | 42.2 | 24.7 | 8.2 | 149.4 | |
| Cho 2020 | GEM 50 mg + MET + INS | 188 | 61.1 | 32.4 | 26.7 | 8.4 | 144.8 |
| PBO + MET + INS | 95 | 59 | 30.5 | 26.8 | 8.4 | 137.3 | |
| Rhee 2013 | GEM 25 mg bid | 136 | 51.8 | 50 | 25.9 | 8.13 | 151.9 |
| GEM 50 mg | 135 | 53.9 | 60 | 25.6 | 8.01 | 145 | |
| SIT 100 mg | 133 | 52.9 | 53.4 | 26.3 | 8.06 | 146.9 | |
| Park 2017 | GEM 50 mg | 24 | 48.9 | 71 | 26.6 | 9.5 | 183 |
| SIT 100 mg | 21 | 49.6 | 76 | 25.9 | 9.1 | 181 | |
| GLIM 2 mg | 21 | 51.5 | 71 | 26 | 9.7 | 202 | |
| Han 2018 | GEM 50 mg | 48 | 62.2 | 64.6 | 26 | 8.4 | 162.3 |
| LINA 5 mg | 52 | 62.6 | 63.5 | 26.7 | 8.4 | 150 | |
| Jung 2018 | GEM 25 mg bid | 58 | 51.6 | 55.2 | 26 | 8.2 | 152.3 |
| GEM 50 mg | 55 | 54.6 | 60 | 25.5 | 7.9 | 139.3 | |
| SIT 100 mg | 44 | 51.8 | 54.5 | 26.6 | 8.08 | 149.26 | |
| Kwak 2020 | GEM 50 mg | 34 | 53.6 | 58.8 | 26 | 7.9 | NA |
| DAPA 10 mg | 36 | 50.5 | 72.2 | 25.6 | 7.9 | NA |
GEM gemigliptin, SIT sitagliptin, LINA linagliptin, MET metformin, GLIM glimepiride, DAPA dapagliflozin, INS insulin, bid twice a day.